Kanada - Kiingereza - Health Canada

eli lilly and company limited - insulin isophane (nph) - liquid - 100unit - insulin isophane (nph) 100unit - insulins

Kanada - Kiingereza - Health Canada

eli lilly and company limited - insulin isophane nph pork - liquid - 100unit - insulin isophane nph pork 100unit - insulins

Marekani - Kiingereza - NLM (National Library of Medicine)

pfizer inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - kit - 1 mg - exubera is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. exubera has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. in patients with type 1 diabetes, exubera should be used in regimens that include a longer-acting insulin. in patients with type 2 diabetes, exubera can be used as monotherapy or in combination with oral agents or longer-acting insulins. exubera is contraindicated in patients hypersensitive to exubera or one of its excipients. exubera is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting exubera therapy. if a patient starts or resumes smoking, exubera must be discontinued immediately due to the increased risk of hypoglycemia, and an alternative treatment must be utilized (see clinical pharmacology, special populations, smoking). the safety and efficacy of exube

Malta - Kiingereza - Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Marekani - Kiingereza - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin -

Marekani - Kiingereza - NLM (National Library of Medicine)

novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general

Marekani - Kiingereza - NLM (National Library of Medicine)

eli lilly and company - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.5)] . risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7% and has been reported to be as high as 20-25% in women with a hba1c >10%. the estimated background risk of miscarriage for the indicated population is unkn

Israeli - Kiingereza - Ministry of Health

eli lilly israel ltd, israel - insulin lispro - solution for injection - insulin lispro 100 u/ml - insulin lispro - insulin lispro - humalog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog is also indicated for the initial stabilization of diabetes mellitus.

Israeli - Kiingereza - Ministry of Health

eli lilly israel ltd, israel - insulin lispro - solution for injection - insulin lispro 100 u/ml - insulin lispro - insulin lispro - humalog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. humalog is also indicated for the initial stabilization of diabetes mellitus.